Nanoliposome compositions and methods of using the same

A method of reducing one or more proinflammatory or prothrombotic cytokines, the method comprising administering to a subject with a cerebrovascular disease or an aging-related degenerative disease a therapeutically effective amount of a composition comprising a nanoliposome and GM1, wherein the nanoliposome comprises a phospholipid and cholesterol, wherein the phospholipid, the cholesterol, and the GM1 are present in a molar ratio of 70:25:5, respectively, thereby reducing one or more proinflammatory or prothrombotic cytokines.

A method of reversing or reducing neuroinflammation, the method comprising administering to a subject with a cerebrovascular disease or an aging-related degenerative disease a therapeutically effective amount of:

• a composition comprising a nanoliposome and GM1, wherein the nanoliposome comprises a phospholipid and cholesterol, wherein the phospholipid, the cholesterol, and the GM1 are present in a molar ratio of 70:25:5, respectively, thereby reversing or reducing neuroinflammation.

50-54. (canceled)

A method of detecting a medin protein or a fragment thereof in a sample, the method comprising, contacting a medin-modifying nanoliposome wherein the medin-modifying nanoliposome comprises a phospholipid, cholesterol and GM1, wherein the phospholipid, the cholesterol, and the GM1 are present in a molar ratio of 70:25:5 or a nanoliposome comprising a medin binding moiety with the sample, wherein the medin-modifying nanoliposome or the nanoliposome comprising a medin binding moiety comprises a detectable label, wherein the sample comprises a detectable level of the medin protein, and detecting binding of the medin-modifying nanoliposome or the nanoliposome comprising a medin binding moiety to the medin protein.